Toll Free: 1-888-928-9744

Cervical Cancer - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 441 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cervical Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cervical Cancer - Pipeline Review, H1 2016', provides an overview of the Cervical Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Cancer
- The report reviews pipeline therapeutics for Cervical Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Cervical Cancer therapeutics and enlists all their major and minor projects
- The report assesses Cervical Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Cervical Cancer

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 7 Cervical Cancer Overview 8 Therapeutics Development 9 Cervical Cancer - Therapeutics under Development by Companies 11 Cervical Cancer - Therapeutics under Investigation by Universities/Institutes 16 Cervical Cancer - Pipeline Products Glance 17 Cervical Cancer - Products under Development by Companies 20 Cervical Cancer - Products under Investigation by Universities/Institutes 26 Cervical Cancer - Companies Involved in Therapeutics Development 27 Cervical Cancer - Therapeutics Assessment 97 Drug Profiles 112 Cervical Cancer - Recent Pipeline Updates 295 Cervical Cancer - Dormant Projects 415 Cervical Cancer - Discontinued Products 420 Cervical Cancer - Product Development Milestones 421 Appendix 428
List of Tables
Number of Products under Development for Cervical Cancer, H1 2016 21 Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 23 Number of Products under Development by Companies, H1 2016 (Contd..1) 24 Number of Products under Development by Companies, H1 2016 (Contd..2) 25 Number of Products under Development by Companies, H1 2016 (Contd..3) 26 Number of Products under Development by Companies, H1 2016 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H1 2016 28 Comparative Analysis by Late Stage Development, H1 2016 29 Comparative Analysis by Clinical Stage Development, H1 2016 30 Comparative Analysis by Early Stage Development, H1 2016 31 Products under Development by Companies, H1 2016 32 Products under Development by Companies, H1 2016 (Contd..1) 33 Products under Development by Companies, H1 2016 (Contd..2) 34 Products under Development by Companies, H1 2016 (Contd..3) 35 Products under Development by Companies, H1 2016 (Contd..4) 36 Products under Development by Companies, H1 2016 (Contd..5) 37 Products under Investigation by Universities/Institutes, H1 2016 38 Cervical Cancer - Pipeline by 3SBio Inc., H1 2016 39 Cervical Cancer - Pipeline by Admedus Ltd, H1 2016 40 Cervical Cancer - Pipeline by Advaxis, Inc., H1 2016 41 Cervical Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 42 Cervical Cancer - Pipeline by AnGes MG, Inc., H1 2016 43 Cervical Cancer - Pipeline by Antigen Express, Inc., H1 2016 44 Cervical Cancer - Pipeline by Arbor Vita Corporation, H1 2016 45 Cervical Cancer - Pipeline by ArQule, Inc., H1 2016 46 Cervical Cancer - Pipeline by AstraZeneca Plc, H1 2016 47 Cervical Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 48 Cervical Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016 49 Cervical Cancer - Pipeline by Blirt S.A., H1 2016 50 Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 51 Cervical Cancer - Pipeline by Cancer Research Technology Limited, H1 2016 52 Cervical Cancer - Pipeline by Cellceutix Corporation, H1 2016 53 Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 54 Cervical Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016 55 Cervical Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 56 Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2016 57 Cervical Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016 58 Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 59 Cervical Cancer - Pipeline by EirGenix Inc., H1 2016 60 Cervical Cancer - Pipeline by Eisai Co., Ltd., H1 2016 61 Cervical Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016 62 Cervical Cancer - Pipeline by EyeGene, Inc., H1 2016 63 Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 64 Cervical Cancer - Pipeline by Formune S.L., H1 2016 65 Cervical Cancer - Pipeline by Genexine, Inc., H1 2016 66 Cervical Cancer - Pipeline by Genmab A/S, H1 2016 67 Cervical Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 68 Cervical Cancer - Pipeline by Genticel S.A., H1 2016 69 Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 70 Cervical Cancer - Pipeline by Immunovaccine, Inc., H1 2016 71 Cervical Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 72 Cervical Cancer - Pipeline by Johnson & Johnson, H1 2016 73 Cervical Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 74 Cervical Cancer - Pipeline by Kite Pharma, Inc., H1 2016 75 Cervical Cancer - Pipeline by LondonPharma Ltd, H1 2016 76 Cervical Cancer - Pipeline by Mabion SA, H1 2016 77 Cervical Cancer - Pipeline by MedImmune, LLC, H1 2016 78 Cervical Cancer - Pipeline by MEI Pharma, Inc., H1 2016 79 Cervical Cancer - Pipeline by Mundipharma International Ltd, H1 2016 80 Cervical Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 81 Cervical Cancer - Pipeline by Nanotherapeutics, Inc., H1 2016 82 Cervical Cancer - Pipeline by Nektar Therapeutics, H1 2016 83 Cervical Cancer - Pipeline by Novartis AG, H1 2016 84 Cervical Cancer - Pipeline by Oncobiologics, Inc., H1 2016 85 Cervical Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 86 Cervical Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 87 Cervical Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 88 Cervical Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016 89 Cervical Cancer - Pipeline by Pfizer Inc., H1 2016 90 Cervical Cancer - Pipeline by Psicofarma S.A. de C.V., H1 2016 91 Cervical Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 92 Cervical Cancer - Pipeline by Samyang Holdings Corporation, H1 2016 93 Cervical Cancer - Pipeline by Sanofi, H1 2016 94 Cervical Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 95 Cervical Cancer - Pipeline by Seattle Genetics, Inc., H1 2016 96 Cervical Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 97 Cervical Cancer - Pipeline by Shantha Biotechnics Limited, H1 2016 98 Cervical Cancer - Pipeline by Sirnaomics, Inc., H1 2016 99 Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 100 Cervical Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 101 Cervical Cancer - Pipeline by Theravectys SA, H1 2016 102 Cervical Cancer - Pipeline by Tomegavax, Inc., H1 2016 103 Cervical Cancer - Pipeline by UbiVac, LLC, H1 2016 104 Cervical Cancer - Pipeline by Vaccibody AS, H1 2016 105 Cervical Cancer - Pipeline by VLPbio, H1 2016 106 Cervical Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H1 2016 107 Cervical Cancer - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 108 Assessment by Monotherapy Products, H1 2016 109 Assessment by Combination Products, H1 2016 110 Number of Products by Stage and Target, H1 2016 112 Number of Products by Stage and Mechanism of Action, H1 2016 117 Number of Products by Stage and Route of Administration, H1 2016 121 Number of Products by Stage and Molecule Type, H1 2016 123 Cervical Cancer Therapeutics - Recent Pipeline Updates, H1 2016 307 Cervical Cancer - Dormant Projects, H1 2016 427 Cervical Cancer - Dormant Projects (Contd..1), H1 2016 428 Cervical Cancer - Dormant Projects (Contd..2), H1 2016 429 Cervical Cancer - Dormant Projects (Contd..3), H1 2016 430 Cervical Cancer - Dormant Projects (Contd..4), H1 2016 431 Cervical Cancer - Discontinued Products, H1 2016 432


List of Figures
Number of Products under Development for Cervical Cancer, H1 2016 21 Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 23 Number of Products under Investigation by Universities/Institutes, H1 2016 28 Comparative Analysis by Late Stage Development, H1 2016 29 Comparative Analysis by Clinical Stage Development, H1 2016 30 Comparative Analysis by Early Stage Products, H1 2016 31 Assessment by Monotherapy Products, H1 2016 109 Assessment by Combination Products, H1 2016 110 Number of Products by Top 10 Targets, H1 2016 111 Number of Products by Stage and Top 10 Targets, H1 2016 111 Number of Products by Top 10 Mechanism of Actions, H1 2016 116 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 116 Number of Products by Top 10 Routes of Administration, H1 2016 120 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 120 Number of Products by Top 10 Molecule Types, H1 2016 122 Number of Products by Stage and Top 10 Molecule Types, H1 2016 122

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify